The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Minocycline to Improve Neurologic Outcome in Stroke (MINOS): A Dose-Finding Study
Open accessAbstract
Background and Purpose— Minocycline is a promising anti-inflammatory and protease inhibitor that is effective in multiple preclinical stroke models. We conducted an early phase trial of intravenous minocycline in acute ischemic stroke. Methods— Following an open-label, dose-escalation design, minocycline was administered intravenously within 6 hours of stroke symptom onset in preset dose tiers of 3, 4.5, 6, or 10 mg/kg daily over 72 hours. Minocycline concentrations for pharmacokinetic analysis were measured in a subset of patients. Subjects were followed for 90 days. Results— Sixty patients were enrolled, 41 at the highest dose tier of 10 mg/kg. Overall age (65±13.7 years), race (83% white), and sex (47% female) were consistent across the doses. The mean baseline National Institutes of Health Stroke Scale score was 8.5±5.8 and 60% received tissue plasminogen activator. Minocycline infusion was well tolerated with only 1 dose limiting toxicity at the 10-mg/kg dose. No severe hemorrhages occurred in tissue plasminogen activator-treated patients. Pharmacokinetic analysis (n=22) revealed a half-life of approximately 24 hours and linearity of parameters over doses. Conclusions— Minocycline is safe and well tolerated up to doses of 10 mg/kg intravenously alone and in combination with tissue plasminogen activator. The half-life of minocycline is approximately 24 hours, allowing every 24-hour dosing. Minocycline may be an ideal agent to use with tissue plasminogen activator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684
Cited by
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
Chamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00114-9 · Cited by 1,198
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
The immunology of acute stroke
Chamorro, Á., Meisel, A., Planas, A. M., Urra, X., van de Beek, D., & Veltkamp, R. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.98 · Cited by 707
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
Stroke and the immune system: from pathophysiology to new therapeutic strategies
Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U., & Vivien, D. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70066-7 · Cited by 560
Neurological Diseases in Relation to the Blood–Brain Barrier
Rosenberg, G. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.197 · Cited by 445
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury
Casha, S., Zygun, D., McGowan, M. D., Bains, I., Yong, V. W., & John Hurlbert, R. (2012) · Brain · doi:10.1093/brain/aws072 · Cited by 408
Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
Lakhan, S. E., Kirchgessner, A., Tepper, D., & Leonard, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00032 · Cited by 384
Immune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Fields, G. B. (2019) · Cells · doi:10.3390/cells8090984 · Cited by 299
Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score
Strbian, D., Engelter, S., Michel, P., Meretoja, A., Sekoranja, L., Ahlhelm, F. J., Mustanoja, S., Kuzmanovic, I., Sairanen, T., Forss, N., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23546 · Cited by 289
Inflammatory Disequilibrium in Stroke
Petrovic-Djergovic, D., Goonewardena, S. N., & Pinsky, D. J. (2016) · Circulation Research · doi:10.1161/circresaha.116.308022 · Cited by 265
Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside
Sutherland, B. A., Minnerup, J., Balami, J. S., Arba, F., Buchan, A. M., & Kleinschnitz, C. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00770.x · Cited by 259
Neuroinflammation and Cerebrovascular Disease in Old Age: A Translational Medicine Perspective
Di Napoli, M., & Shah, I. M. (2011) · Journal of Aging Research · doi:10.4061/2011/857484 · Cited by 263
Inflammatory Responses in Brain Ischemia
Kawabori, M., & Yenari, M. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150209154036 · Cited by 262
Noninvasive Molecular Imaging of Neuroinflammation
Jacobs, A. H., Tavitian, B., & the INMiND consortium (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.53 · Cited by 245
Matrix metalloproteinases as therapeutic targets for stroke
Yang, Y., & Rosenberg, G. A. (2015) · Brain Research · doi:10.1016/j.brainres.2015.04.024 · Cited by 246
Minocycline development for acute ischemic stroke
Fagan, S. C., Cronic, L. E., & Hess, D. C. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0072-6 · Cited by 100
Self-citationThe Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke
Wicks, E. E., Ran, K. R., Kim, J. E., Xu, R., Lee, R. P., & Jackson, C. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897022 · Cited by 92
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
Metadata
- Authors
- Fagan, S. C., Waller, J. L., Nichols, F. T., Edwards, D. J., Pettigrew, L. C., Clark, W. M., Hall, C. E., Switzer, J. A., Ergul, A., & Hess, D. C.
- Venue
- Stroke
- Published
- 2010-10
- Volume
- 41
- Issue
- 10
- Pages
- 2283-2287
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2163185647
- Cited by
- 244
- References
- 1
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.